Gabather: TOTEMS-study delayed, not derailed - VH Corp
* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share
ANNONS
Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with the clinical trial material. Meanwhile, changes have taken place in the company’s board, with a new chairman being elected. Despite challenges, we maintain our fair value of SEK 0,092 per share.
